Details of the Drug

General Information of Drug (ID: DMI5678)

Drug Name
Pirbuterol
Synonyms
Maxair; Pirbuterolum; Pyrbuterol; Pirbuterol acetate salt; CP 24315-1; Maxair (TN); Pirbuterol (INN); Pirbuterol [INN:BAN]; Pirbuterolum [INN-Latin]; CP-24315-1; CP-24,314-1; CP-24,314-14; 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-tert-butylamino ethyl)pyridine, dihydrochloride; 2-tert-Butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)ethanol; 6-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)-3-pyridinol; 6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Approved [1]
Bronchiectasis CA24 Approved [2]
Bronchitis CA20 Approved [2]
Pulmonary disease 1B10-1F85 Approved [2]
Pulmonary emphysema CA21.Z Approved [2]
Severe asthma CA23 Approved [2]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Bronchodilator Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 240.3
Logarithm of the Partition Coefficient (xlogp) -0.1
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 2 hours [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.14268 micromolar/kg/day [4]
Chemical Identifiers
Formula
C12H20N2O3
IUPAC Name
6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol
Canonical SMILES
CC(C)(C)NCC(C1=NC(=C(C=C1)O)CO)O
InChI
InChI=1S/C12H20N2O3/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8/h4-5,11,13,15-17H,6-7H2,1-3H3
InChIKey
VQDBNKDJNJQRDG-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4845
ChEBI ID
CHEBI:8245
CAS Number
38677-81-5
DrugBank ID
DB01291
TTD ID
D0SS4P
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor beta-2 (ADRB2) TT2CJVK ADRB2_HUMAN Agonist [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Gene/Protein Processing [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Asthma
ICD Disease Classification CA23
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Adrenergic receptor beta-2 (ADRB2) DTT ADRB2 4.88E-01 -0.05 -0.12
Adrenergic receptor beta-2 (ADRB2) DTT ADRB2 7.10E-01 0.06 0.09
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Pirbuterol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Moderate Additive hypertensive effects by the combination of Pirbuterol and Methylene blue. Acquired methaemoglobinaemia [3A93] [7]
Ivosidenib DM8S6T7 Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Ivosidenib. Acute myeloid leukaemia [2A60] [8]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Pirbuterol and Midostaurin. Acute myeloid leukaemia [2A60] [8]
Arn-509 DMT81LZ Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Arn-509. Acute myeloid leukaemia [2A60] [8]
Gilteritinib DMTI0ZO Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Gilteritinib. Acute myeloid leukaemia [2A60] [8]
Oliceridine DM6MDCF Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Oliceridine. Acute pain [MG31] [9]
Ivabradine DM0L594 Moderate Increased risk of prolong QT interval by the combination of Pirbuterol and Ivabradine. Angina pectoris [BA40] [8]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Pirbuterol and Droxidopa. Autonomic nervous system disorder [8D87] [10]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Pirbuterol and Retigabine. Behcet disease [4A62] [9]
Eribulin DM1DX4Q Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Eribulin. Breast cancer [2C60-2C6Y] [8]
Bosutinib DMTI8YE Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Bosutinib. Breast cancer [2C60-2C6Y] [8]
Levomilnacipran DMV26S8 Moderate Increased risk of rapid heart rate by the combination of Pirbuterol and Levomilnacipran. Chronic pain [MG30] [11]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Pirbuterol and Probucol. Coronary atherosclerosis [BA80] [9]
Pasireotide DMHM7JS Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Pasireotide. Cushing syndrome [5A70] [8]
Milnacipran DMBFE74 Moderate Increased risk of rapid heart rate by the combination of Pirbuterol and Milnacipran. Depression [6A70-6A7Z] [11]
Desvenlafaxine DMHD4PE Moderate Additive hypertensive effects by the combination of Pirbuterol and Desvenlafaxine. Depression [6A70-6A7Z] [11]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Pirbuterol and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [8]
Deutetrabenazine DMUPFLI Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Deutetrabenazine. Dystonic disorder [8A02] [8]
Ingrezza DMVPLNC Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Ingrezza. Dystonic disorder [8A02] [8]
Solifenacin DMG592Q Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Solifenacin. Functional bladder disorder [GC50] [8]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Pirbuterol and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [8]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Pirbuterol and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [9]
Rilpivirine DMJ0QOW Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [8]
Crizotinib DM4F29C Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Crizotinib. Lung cancer [2C25] [8]
Ceritinib DMB920Z Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Ceritinib. Lung cancer [2C25] [8]
Osimertinib DMRJLAT Moderate Increased risk of prolong QT interval by the combination of Pirbuterol and Osimertinib. Lung cancer [2C25] [8]
Selpercatinib DMZR15V Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Selpercatinib. Lung cancer [2C25] [9]
Lumefantrine DM29GAD Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Lumefantrine. Malaria [1F40-1F45] [9]
Hydroxychloroquine DMSIVND Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Hydroxychloroquine. Malaria [1F40-1F45] [8]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [8]
Vemurafenib DM62UG5 Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Vemurafenib. Melanoma [2C30] [8]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Pirbuterol and LGX818. Melanoma [2C30] [8]
Panobinostat DM58WKG Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Panobinostat. Multiple myeloma [2A83] [8]
Siponimod DM2R86O Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Siponimod. Multiple sclerosis [8A40] [8]
Fingolimod DM5JVAN Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Fingolimod. Multiple sclerosis [8A40] [8]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Ozanimod. Multiple sclerosis [8A40] [12]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Pirbuterol and Romidepsin. Mycosis fungoides [2B01] [9]
Nilotinib DM7HXWT Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Nilotinib. Myeloproliferative neoplasm [2A20] [8]
Entrectinib DMMPTLH Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Entrectinib. Non-small cell lung cancer [2C25] [9]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Pirbuterol and Lofexidine. Opioid use disorder [6C43] [8]
Rucaparib DM9PVX8 Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Rucaparib. Ovarian cancer [2C73] [8]
Triclabendazole DMPWGBR Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Triclabendazole. Parasitic worm infestation [1F90] [9]
Safinamide DM0YWJC Moderate Additive hypertensive effects by the combination of Pirbuterol and Safinamide. Parkinsonism [8A00] [7]
Rasagiline DM3WKQ4 Moderate Additive hypertensive effects by the combination of Pirbuterol and Rasagiline. Parkinsonism [8A00] [7]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Pirbuterol and Pimavanserin. Parkinsonism [8A00] [8]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Pirbuterol and Macimorelin. Pituitary gland disorder [5A60-5A61] [13]
Lefamulin DME6G97 Moderate Increased risk of prolong QT interval by the combination of Pirbuterol and Lefamulin. Pneumonia [CA40] [8]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Pirbuterol and Degarelix. Prostate cancer [2C82] [8]
ABIRATERONE DM8V75C Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and ABIRATERONE. Prostate cancer [2C82] [8]
Enzalutamide DMGL19D Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Enzalutamide. Prostate cancer [2C82] [8]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Pirbuterol and Levomepromazine. Psychotic disorder [6A20-6A25] [9]
Ciclesonide DM2NA4K Minor Increased risk of hypokalemia by the combination of Pirbuterol and Ciclesonide. Respiratory system disease [CB40-CB7Z] [14]
Iloperidone DM6AUFY Moderate Increased risk of prolong QT interval by the combination of Pirbuterol and Iloperidone. Schizophrenia [6A20] [8]
Amisulpride DMSJVAM Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Amisulpride. Schizophrenia [6A20] [8]
Asenapine DMSQZE2 Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Asenapine. Schizophrenia [6A20] [8]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Pirbuterol and LEE011. Solid tumour/cancer [2A00-2F9Z] [15]
Vandetanib DMRICNP Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [8]
Triptorelin DMTK4LS Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [8]
Pitolisant DM8RFNJ Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Pitolisant. Somnolence [MG42] [8]
Telavancin DM58VQX Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [8]
Lenvatinib DMB1IU4 Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Lenvatinib. Thyroid cancer [2D10] [8]
Cabozantinib DMIYDT4 Moderate Increased risk of ventricular arrhythmias by the combination of Pirbuterol and Cabozantinib. Thyroid cancer [2D10] [8]
Fluticasone DMGCSVF Minor Increased risk of hypokalemia by the combination of Pirbuterol and Fluticasone. Vasomotor/allergic rhinitis [CA08] [14]
⏷ Show the Full List of 63 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7272).
2 Pirbuterol FDA Label
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Inhaled beta agonists. Respir Care. 2007 Jul;52(7):820-32.
6 Development of 3D-QSAR models for predicting the activities of chemicals to stimulate muscle growth via (2)-adrenoceptor. Toxicol In Vitro. 2021 Dec;77:105251. doi: 10.1016/j.tiv.2021.105251. Epub 2021 Sep 30.
7 Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
8 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
9 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
10 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
11 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
12 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
13 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
14 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
15 Canadian Pharmacists Association.